Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Toshiki Iwai"'
Autor:
Toshiki Iwai, Masamichi Sugimoto, Namrata S. Patil, Daniel Bower, Miho Suzuki, Chie Kato, Keigo Yorozu, Mitsue Kurasawa, David S. Shames, Osamu Kondoh
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-15 (2021)
Abstract Anti-PD-L1 antibodies benefit many cancer patients, even those with “non-inflamed tumor”. Determining which patients will benefit remains an important clinical goal. In a non-inflamed tumor mouse model, we found that PD-L1 was highly exp
Externí odkaz:
https://doaj.org/article/4b94adbd323b4bf69ee418f876c26582
Publikováno v:
Molecular Cancer Therapeutics. 20:2519-2526
Immune-related pneumonitis is an important toxicity associated with checkpoint inhibitor therapy with anti–PD-1 or anti–PD-L1 antibodies, often necessitating discontinuation of treatment. Development of methods to mitigate checkpoint inhibitor–
Autor:
Takahiro Fukuda, Sung-Won Kim, Takaaki Chou, Hisashi Sakamaki, Toshiki Iwai, Yasuo Morishima, Hirofumi Taji, Ritsuro Suzuki, Kinuko Tajima, Junji Suzumiya, Yoshitaka Asakura
Publikováno v:
International Journal of Hematology. 111:256-266
To investigate the use of high-dose therapy and autologous stem cell transplantation (ASCT) for relapsed or high-risk diffuse large B-cell lymphoma (DLBCL) between 1990 and 2007, we conducted a nationwide survey using the registry database of the Jap
Autor:
Keigo Yorozu, Yoshihito Tashiro, Yukari Matsuo-Tezuka, Yusuke Sasaki, Toshiki Iwai, Michinori Hirata, Mitsue Kurasawa
Publikováno v:
Contrast Media & Molecular Imaging. 2019:1-7
Aim. Iron overload is a life-threatening disorder that can increase the risks of cancer, cardiovascular disease, and liver cirrhosis. There is also a risk of iron overload in patients with chronic kidney disease. In patients with renal failure, iron
Publikováno v:
IEEJ Transactions on Electrical and Electronic Engineering. 16:653-655
Autor:
David S. Shames, Keigo Yorozu, Mitsue Kurasawa, Masamichi Sugimoto, Namrata Patil, Chie Kato, Toshiki Iwai, Osamu Kondoh, Daniel Bower, Miho Suzuki
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-15 (2021)
Scientific Reports
Scientific Reports
Anti-PD-L1 antibodies benefit many cancer patients, even those with “non-inflamed tumor”. Determining which patients will benefit remains an important clinical goal. In a non-inflamed tumor mouse model, we found that PD-L1 was highly expressed on
Autor:
Nobuhiko Uoshima, Tomoko Takimoto-Shimomura, Mitsushige Nakao, Hitoji Uchiyama, Shin-ichi Fuchida, Hisao Nagoshi, Hiroto Kaneko, Kazuho Shimura, Shinsuke Mizutani, Yoshiaki Chinen, Mio Sugitani, Yosuke Matsumoto, Toshiki Iwai, Eri Kawata, Yutaka Kobayashi, Mihoko Yoshida, Tsutomu Kobayashi, Yuji Shimura, Chihiro Shimazaki, Muneo Ohshiro, Miki Kiyota, Hikari Nishigaki, Masafumi Taniwaki, Junya Kuroda, Shigeo Horiike
Publikováno v:
International Journal of Hematology. 110:77-85
This multicenter phase II study (UMIN000008145) aims to investigate the efficacy and safety of six cycles of combination therapy (RBD) comprising rituximab, bendamustine, and dexamethasone (DEX) for relapsed or refractory (RR) indolent B-cell non-Hod
Autor:
Yosuke Matsumoto, Kodai Kuriyama, Hitoji Uchiyama, Muneo Ohshiro, Taisuke Tsuji, Rina Nishikawa, Toshiki Iwai, Yoshiko Hirakawa, Hiroaki Nagata, Mio Sugitani, Yoshimi Kitamura
Publikováno v:
Current Problems in Cancer. 46:100813
We herein report the rare case of a 72-year-old female who presented with paraneoplastic pemphigus (PNP) and bronchiolitis obliterans (BO) associated with follicular lymphoma (FL), who was successfully treated with obinutuzumab (GA101; G) and bendamu
Autor:
Toshiki Iwai, Wataru Fukuda, Rina Nishikawa, Mio Yamamoto-Sugitani, Tsutomu Kobayashi, Muneo Ohshiro, Kodai Kuriyama, Yosuke Matsumoto, Yuji Shimura, Taku Tsukamoto, Shinsuke Mizutani, Hitoji Uchiyama, Yoshiko Fujimoto-Hirakawa, Hiroaki Nagata, Junya Kuroda
Publikováno v:
Annals of Hematology. 100:2849-2850
Autor:
Daiko Wakita, Masamichi Sugimoto, Mitsue Kurasawa, Kaname Yamamoto, Keigo Yorozu, Toshiki Iwai
Publikováno v:
Oncotarget
Anti-PD-L1 antibodies inhibit interactions between PD-L1 and PD-1 and interactions between PD-L1 and B7-1, thereby reinvigorating anticancer immunity. Although there are numerous ongoing clinical studies evaluating combinations of standard chemothera